As shown in Fig. 4A, compared with 1.0 μmol/l imatinib for 24 to 72 h, 1.5 μmol/l imatinib resulted in more activated caspase-3 in a higher percentage of CD34+ cells from patients with CML in the megakaryocytic crisis phase in a dose- and time-dependent manner. The gene discussed is CASP3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.